• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Finance

Finance

Danone further invests in next-generation biotics with acquisition of The Akkermansia Company

June 26, 2025 Microbiome Times

Danone announces the acquisition of The Akkermansia Company (TAC), a Belgian company with nearly 20 years of history and science, specializing in biotics. In 2004, the team of Professor Willem M. de Vos at Wageningen University discovered, […]

Finance

32 Biosciences receives $6 million in funding to advance gut microbiome platform technologies

June 11, 2025 Microbiome Times

32 Biosciences announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key […]

Finance

MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®

June 3, 2025 Microbiome Times

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the […]

Finance

Microba Delivers Landmark IBD Results & Signs Major Gastro Partner

April 29, 2025 Microbiome Times

Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership […]

Finance

PepsiCo to Acquire fast-growing prebiotic soda brand for $1.95 billion

March 21, 2025 Microbiome Times

PepsiCo, Inc. (NASDAQ: PEP) (“PepsiCo”) announced on Monday that it has entered into a definitive agreement to acquire poppi, a fast-growing prebiotic soda brand, for $1.95 billion, including $300 million of anticipated cash tax benefits for a […]

Finance

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

February 26, 2025 Microbiome Times

BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a securities purchase agreement […]

Finance

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round

January 15, 2025 Microbiome Times

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E financing round. The […]

Finance

SNIPR Biome receives up to €20 million European backing to advance therapies AMR

December 10, 2024 Microbiome Times

Danish biotech SNIPR Biome will get up to €20 venture debt from the European Investment Bank (EIB) to step up Europe’s fight against antimicrobial resistance to medicines. The company will use the EIB credit to […]

Finance

UCalgary startup Taylored Biotherapeutics to commercialize psychobiotic therapies

December 2, 2024 Microbiome Times

Taylored Biotherapeutics, founded by UCalgary’s Dr. Valerie Taylor, MD, PhD, and supported by Chief Operating Officer Asem Bala, has achieved a significant milestone by securing a $100,000 grant from the Ontario Brain Institute (OBI). This award, part of OBI’s highly competitive Neurotech […]

Finance

Cmbio: A New Brand Unifying Global Leaders in Microbiome and Metabolomics Science

November 19, 2024 Microbiome Times

Today marks the launch of Cmbio, a new brand that brings together Clinical Microbiomics (Europe), CosmosID (North America), MS-Omics (Europe), DNASense (Europe), and Microba’s Research Services Unit (Australia and Asia) under one identity. United under […]

Finance

Freya Biosciences Announces $10.4 Million Strategic Investment from the Bill & Melinda Gates Foundation

November 19, 2024 Microbiome Times

The new investment extends Series A investment to about $50 million Freya Biosciences, a transatlantic biotech company specializing in women’s health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation […]

Posts navigation

« 1 2 3 … 32 »

Sign Up to Free Newsletter

QIAGEN WEBINAR SERIES – REGISTER HERE

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
    May 1, 2026
  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
sign up

Sign up to the Microbiome Times newsletter